The hardy chocolate vine, also known as five-leaf Akebia, grows vigorously on a trellis or fence and provides a thick screen of green leaves and fragrant purple blooms in early summer. It spreads ...

If you've got the perfect spot to grow a beautiful vining plant, it's important to know which ones support the ecosystem and those that can cause harm.

CAMBRIDGE, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ®, Inc. (“Akebia”) (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted ...

Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to break-even earnings per share a year ago.

Akebia Therapeutics' stock is down 28% after a proposed stock offering, with declining Auryxia revenues and significant financial challenges. Vafseo's market launch shows some promise, but it's a ...

(AP) — Akebia Therapeutics Inc. (AKBA ... The kidney disease treatment developer posted revenue of $46.5 million in the period. Advertisement Article continues below this ad For the year ...

Akebia Therapeutics has a 52-week low of $0.80 and a 52-week high of $2.58. Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last announced its quarterly earnings results on Thursday, March 13th.

Piper Sandler raised the firm’s price target on Akebia (AKBA) to $6 from $4 and keeps an Overweight rating on the shares. The firm says it remains a buyer of Akebia shares following Q4 reporting ...

The options have an exercise price of $1.92 per share, which is equal to the closing price of Akebia’s common stock on the grant date. The stock options vest over four years, with 25% of the ...

Five Below issued an upbeat outlook for its current ... Shares surge 51%, to $23.40, in post-market trading. Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical ...